The latest updates on prescription drugs and ways to save from the GoodRx medical team

New GoodRx Top 10 Drug Guide

by Elizabeth Davis on June 5, 2015 at 9:31 am

Our new top 10 lists are in for the most-dispensed and most expensive prescriptions in the US—take a look at these interesting updates.

Which prescriptions have been filled the most in 2015 so far?

Based on a sample of claims reported by pharmacies across the country, thyroid meds like Synthroid and levothyroxine near the top of the list, while standard heart and diabetes prescriptions lisinopril (Zestril, Prinivil), atorvastatin (Lipitor), and metformin (Glucophage) are still very frequently prescribed—no surprises there. For the first time though, anti-nausea treatment ondansetron (Zofran) also makes an appearance. Take a look at the full list to see what else people are filling.

And which prescriptions are the most expensive?

The costly—but effective—new hepatitis C meds like HarvoniSovaldi, Olysio, and Viekira Pak are still topping the list, along with treatments for rare conditions like hereditary andioedema (HAE) and familial hypercholesterolemia (an inherited form of high cholesterol). Harvoni is still the most expensive per month based on actual pharmacy claims, up to a shocking $82,000—with an even higher total for a full 8-week, 12-week, or 24-week course. See the full list for more.

Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.